The pharmacologic management of HFpEF is an evolving field. Symptomatic management
with diuretics and optimization of comorbidities remain important components of therapy …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a common condition in clinical
practice, affecting more than half of patients with HF. HFpEF is associated with morbidity and …

Background Obesity and insulin resistance are prevalent in heart failure with preserved
ejection fraction (HFpEF) and are associated with adverse cardiovascular outcomes …

Beta blockers (BBs) play a crucial role in enhancing the quality of life and extending the
survival of patients with heart failure and reduced ejection fraction (HFrEF). Initiating the …

Herzinsuffizienz mit erhaltener Ejektionsfraktion („heart failure with preserved ejection
fraction “, HFpEF) ist verantwortlich für rund die Hälfte aller herzinsuffizienzassoziierten …

Rethinking Rehospitalization in Heart Failure Care Transitions: Heterogeneity in Use Typologies
Rethinking Rehospitalization in Heart Failure Care Transitions: Heterogeneity in Use Typologies …

AstraZeneca. FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of
cardiovascular death or worsening heart failure in patients with preserved ejection fraction …